Technical Analysis for DBTX - Decibel Therapeutics, Inc.

Grade Last Price % Change Price Change
F 18.74 4.05% 0.73
DBTX closed down 9.5 percent on Tuesday, February 23, 2021, on 1.31 times normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A N/A
Historical DBTX trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 4.05%
Multiple of Ten Bearish Other 4.05%
New 52 Week Closing High Bullish -5.83%
Multiple of Ten Bearish Other -5.83%
Gapped Up Strength -5.83%
Up 3 Days in a Row Strength -5.83%
Up 4 Days in a Row Strength -5.83%
Up 5 Days in a Row Strength -5.83%
New 52 Week Closing High Bullish -1.63%
Up 3 Days in a Row Strength -1.63%
Older End-of-Day Signals for DBTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 1 hour ago
Up 5% about 1 hour ago
Gapped Up (Partial) about 2 hours ago
Up 3% about 2 hours ago
Up 2% about 2 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Decibel Therapeutics, Inc. Description

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin, or OTOF, gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy, or BVP, by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was founded in 2013 and is based in Boston, Massachusetts.


Keywords: Biotechnology Cancer Biology Chemotherapy Gene Therapy Occupational Safety And Health Hearing Audiology Hearing Loss Deafness Auditory System Balance Disorders Hair Cell

Is DBTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 24.39
52 Week Low 17.67
Average Volume 246,947
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 0.00
Average True Range 0.00
ADX 0.0
+DI 0.00
-DI 0.00
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.09
Resistance 3 (R3) 21.42 20.74 20.57
Resistance 2 (R2) 20.74 19.95 20.57 20.40
Resistance 1 (R1) 19.37 19.47 19.03 19.04 20.23
Pivot Point 18.69 18.69 18.52 18.52 18.69
Support 1 (S1) 17.32 17.90 16.98 16.99 15.79
Support 2 (S2) 16.64 17.42 16.47 15.62
Support 3 (S3) 15.27 16.64 15.45
Support 4 (S4) 14.94